Company Description
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products.
The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.
It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia.
Scienture Holdings, Inc. is based in Tampa, Florida.
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 13, 2020 |
| Industry | Pharmaceutical Retailers |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Shankar Hariharan |
Contact Details
Address: 6308 Benjamin Rd, Suite 708 Tampa, Florida 33634 United States | |
| Phone | 800 261 0281 |
| Website | scienture.com |
Stock Details
| Ticker Symbol | SCNX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001382574 |
| ISIN Number | US80880X1046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Narasimhan Mani M.B.A., Ph.D. | President, Co-Chief Executive Officer and Director |
| Dr. Shankar Hariharan Ph.D. | Founder, Co-Chief Executive Officer and Executive Chairman |
| Eric Sherb C.P.A. | Chief Financial Officer |
| Rahul Surana M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer of Scienture LLC |
| Michele Rath | Senior Vice President and Chief Commercial Officer of Scienture LLC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 1, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 1, 2025 | D | Notice of Exempt Offering of Securities |
| Jul 24, 2025 | 8-K | Current Report |
| Jul 15, 2025 | 1-A-W | Filing |
| Jul 8, 2025 | DRS | [Cover] Draft Registration Statement |
| Jul 3, 2025 | 8-K | Current Report |
| Jun 17, 2025 | EFFECT | Notice of Effectiveness |
| Jun 16, 2025 | POS AM | Post-Effective amendments for registration statement |
| May 22, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |